Clinical Trial

SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Trial Details
NCT Number NCT06544720
Lead Sponsor The Affiliated Hospital of Qingdao University
Conditions Human Papillomavirus Associated Carcinomas, Cervical Cancer, Head and Neck Cancers, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, HPV-Related Malignancy
Enrollment 18 participants
Start Date 2023-08-02
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-09